Winway Health Desk
Founders of molecular diagnostics company ChromaCode share ambitions for their business
ChromaCode Co-Founders Alex Dickinson, Executive Chairman, Aditya Rajagopal, CTO, and CEO Greg Gosch talk about the formation of their molecular testing startup.
Why did you...
Searching for vaccine information? Google wants to make it easier to...
Google plans to highlight local information on vaccine availability through its search engine, starting with the states of Arizona, Louisiana, Mississippi and Texas. Photo...
Merck drops out of the Covid-19 vaccine race after subpar data
Merck is pulling out of the Covid-19 vaccine race.
The New Jersey-based drugmaker announced today it is putting a stop to the development of its...
Dr Fauci: We won’t be able to crush Covid-19 like smallpox...
Dr. Anthony Fauci received the 2021 Luminary Award from the Precision Medicine World Congress on Monday.
Vaccine hesitancy and a slow rollout is a...
FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis
FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis
VICTORIA, British Columbia & ROCKVILLE, Md.-- January 22, 2021 -- Aurinia Pharmaceuticals Inc. today...
Startup targets orphan kidney disease with former Merck drug
Backed by $80 million in Series C funding, Vera Therapeutics is targeting a chronic kidney disease with its first drug candidate, atacicept, a product...
Aurinia snags FDA approval for lupus nephritis med Lupkynis, its first...
Aurinia has nabbed its first FDA approval with an OK for Lupkynis (voclosporin) to treat lupus nephritis, or kidney inflammation caused by systemic lupus erythematosus. And...
How Biden will restore the ACA: 4 potential changes
With the presidency, Senate and House all under the control of the Democrats, the Affordable Care Act is in the safest position it’s been...
Myovant leans on new partner Pfizer as it dives into first...
Myovant Sciences is sporting a new look for 2021: first drug launch, new CEO and a big-time partnership with Pfizer.
The U.K. company's prostate cancer...
Hillrom to buy cardiac monitoring company Bardy Diagnostics for $375M
In another deal for cardiac monitoring, Hillrom (NYSE: HRC) will buy Seattle-based startup Bardy Diagnostics for $375 million. The company, which was founded in...
